知镜 Cognispect · 医学文献与研究工作台

Discovery of 2-((4-(phenylsulfonyl)piperazin-1-yl)methyl)-1H-indole derivative B9, an anti-inflammatory agent targeting acute and chronic inflammation for the treatment of acute lung injury and diabetic kidney disease.

Huang N, Yuan M, Niu Z, Xu Y, Tang D, Dong K, Chen Z, Lv Y, Chen Q, Chen T, Fu D, Mo Y, Zhou Q, Liang G, Tang Q, Dai Q.
European journal of medicinal chemistry · 2026-11-03 · PMID 42998521

文献摘要

Inflammatory diseases constitute a critical category of global health burdens. Acute lung injury (ALI) and diabetic kidney disease (DKD) are representative diseases of acute and chronic inflammatory diseases. Suppression of excessive pro-inflammatory cytokine release represents a promising therapeutic strategy. In this study, we designed and synthesized a series of indole-based derivatives to evaluate their anti-inflammatory potential. Biological evaluation in mouse macrophage (RAW264.7/J774A.1) and human monocytic (THP-1) cells identified compound B9 as the most potent inhibitor on the release of cytokines interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Mechanistic studies demonstrated that B9 suppressed inflammation by inhibiting the NF-κB/MAPK pathways. In vivo toxicity and tissue distribution study showed B9 having favorable safety profile and high concentrations in lung/kidney. In mouse efficacy studies, B9 exerted potent anti-inflammatory efficacy against lipopolysaccharide (LPS)- and cecal ligation and puncture (CLP)-induced ALI. Moreover, B9 conferred prominent renoprotective effects in both type 1 and type 2 DKD mouse models. However, the pharmacokinetic profile of B9 remains suboptimal, warranting further investigation. These findings identified B9 as a lead structure for further development.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。